Trou­bled Alzheimer's play­er Cor­texyme says good­bye to found­ing team as in­de­pen­dent in­vestor takes chair­man­ship

When Cor­texyme’s lead­er­ship got on an an­a­lyst call last Oc­to­ber to dis­cuss the re­sults for their lead Alzheimer’s drugs, many lis­ten­ers were be­wil­dered.

The tri­al had un­equiv­o­cal­ly failed: No dif­fer­ence in cog­ni­tive de­cline was seen be­tween pa­tients on place­bo and pa­tients on their drug. There did seem to be an ef­fect on one sub­group that some neu­rol­o­gists found promis­ing, but that was just the ten­ta­tive ba­sis for a new study, not a de­ci­sive re­sult.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER